Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K071388

    Validate with FDA (Live)

    Manufacturer
    Date Cleared
    2007-11-06

    (172 days)

    Product Code
    Regulation Number
    862.1225
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Gentian Cystatin C Immunoassay is an in-vitro diagnostic test for quantitative determination of cystatin c in human serum and plasma. The measurement of cystatin c is used in the diagnosis and treatment of renal diseases.

    Device Description

    The Gentian cystatin C immunoassay is a particle enhanced turbidimetric immunoassay (PETIA). The immunoparticles are made from activated polystyrene microspheres to which avian anti-human cystatin C antibodies are covalently attached. The immunoparticles and cystatin C form aggregations that change the absorbance signal, depending on the amount of cystatin C present. Measurements obtained by this device are used for the determination of Cystatin C in human serum and plasma. The Gentian C assay is calibrated with human Cystatin C calibrators. Cystatin C controls are assayed for the verification of the accuracy and precision of the Gentian cystatin C immunoassay.

    AI/ML Overview

    Here's a summary of the acceptance criteria and the study details for the Gentian Cystatin C Immunoassay, based on the provided text:

    Acceptance Criteria and Device Performance

    The core of the study is a comparison to a predicate device, the Dade Behring, Inc., N Latex Cystatin C Test Kit (K003503), rather than explicit numerical acceptance criteria for accuracy or precision. The primary acceptance criteria appear to be substantial equivalence, demonstrated by:

    • Acceptable correlation statistics (Slope, Intercept, R-value) when compared to the predicate device across different instruments.
    • Demonstration of comparable performance characteristics such as measuring range, linearity, precision, and interference.
    Acceptance Criteria (Implied for Substantial Equivalence)Reported Device Performance (Gentian Cystatin C Immunoassay vs. Predicate)
    Method Comparison Regression Analysis:
    Slope close to 1.0Study 1:
    Modular P vs. BNII: 1.075
    Modular P vs. BN ProSpec: 1.048
    Study 2:
    Modular P vs. BN ProSpec: 1.021
    Architect vs. BN ProSpec: 0.975
    Intercept close to 0.0Study 1:
    Modular P vs. BNII: 0.009
    Modular P vs. BN ProSpec: 0.059
    Study 2:
    Modular P vs. BN ProSpec: -0.025
    Architect vs. BN ProSpec: -0.059
    R-value close to 1.0Study 1:
    Modular P vs. BNII: 0.986
    Modular P vs. BN ProSpec: 0.992
    Study 2:
    Modular P vs. BN ProSpec: 1.00
    Architect vs. BN ProSpec: 0.989
    Measuring Range:0.3 - 8.0 mg/L
    Linearity:0.34 - 8.4 mg/L (Modular P), 0.27 - 8.8 mg/L (Architect)
    Total Imprecision CV:4.2% (over 20 days with two lots)
    Interference:No significant interference from drugs, anticoagulants, hemoglobin (8 g/L), intralipid (11 g/L), triglycerides (14 g/L), bilirubin (420 mg/L). No RF interference.
    Recovery:99-110%
    Antigen Hook Effect:Not significant below 16 mg/L (patient samples not expected to exceed 9 mg/L)
    Sample Stability:Up to one month at 2-8°C
    Reagent Stability:At least 18 months (reagents at 2-8°C), minimum 4 weeks (reagents in use)
    Limit of Detection (LoD) & Limit of Quantitation (LoQ):Within acceptance criteria and below lowest calibrator concentration.

    Study Information

    1. Sample Size used for the test set and the data provenance:

      • Study 1: 172 (Modular P vs. BNII), 174 (Modular P vs. BN ProSpec)
      • Study 2: 76 (Modular P vs. BN ProSpec), 87 (Architect vs. BN ProSpec)
      • Total N for method comparison: 172 + 174 + 76 + 87 = 509 samples.
      • Data Provenance: Not explicitly stated, but clinical studies are generally implied to be from human blood samples. No country of origin is mentioned, nor whether samples were retrospective or prospective.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • Not applicable. This is an in-vitro diagnostic (IVD) device study comparing the performance of a new assay to a legally marketed predicate assay using patient samples. The "ground truth" here is the measurement from the established predicate device, not clinical expert consensus.
    3. Adjudication method for the test set:

      • Not applicable for this type of IVD comparison study. The study involves quantitative measurements, not subjective evaluations requiring adjudication.
    4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • Not applicable. This is an IVD device for laboratory determination of a biomarker, not an imaging or diagnostic aid for human readers/clinicians, nor does it involve AI.
    5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

      • Yes, this is effectively a standalone performance evaluation of the immunoassay system. It measures the device's ability to accurately quantify Cystatin C in samples.
    6. The type of ground truth used:

      • The "ground truth" for the comparative studies was the results obtained from the predicate device, the Dade Behring, Inc., N Latex Cystatin C Test Kit (K003503). This is a common method for demonstrating substantial equivalence for new IVD assays. Other performance characteristics (linearity, precision, interference) are established against internal analytical standards.
    7. The sample size for the training set:

      • The document does not explicitly mention a "training set" in the context of machine learning or algorithm development. For a turbidimetric immunoassay, the "training" equivalent would be the development and optimization of the assay reagents and conditions, as well as the calibration process with a set of known standards. The sample size for these development and calibration steps is not specified.
    8. How the ground truth for the training set was established:

      • As above, the concept of a training set with "ground truth" established by experts doesn't directly apply here. The assay is calibrated using human Cystatin C calibrators. These calibrators would have known concentrations of Cystatin C, established through highly accurate reference methods (e.g., gravimetric preparation, reference laboratories, or certified reference materials).
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1